ClinicalTrials.gg
Not yet recruitingNCT07949500ESKRAPUpdated Nov 19, 2026

Esketamine Plus Sirolimus for Adults With Depression Who Have Not Responded to Esketamine

A Phase 2 interventional study of Esketamine and Sirolimus (RAPAMUNE) in Treatment Resistant Depression (TRD), sponsored by Rodolfo Furlan Damiano. Not yet recruiting at 2 sites in Brazil. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Rodolfo Furlan Damiano · Phase 2, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Depressive Disorder, Treatment-Resistant with a site in Brazil — 3 open to participants now, 3 under way, none of them phase 3. Depressive Disorder, Treatment-Resistant · Brazil.

Planned enrollment
10th of 11
40 · median 120
Started
2026
with 1 other
Phase 2
2 of 12
1 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Rodolfo Furlan Damiano

Among the 12 studies in Depressive Disorder, Treatment-Resistant with a site in Brazil, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 2, and was the 12th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

3 of the 12 studies in Depressive Disorder, Treatment-Resistant with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Depressive Disorder, Treatment-Resistant with a site in Brazil, or all of them as a file.
02

Study summary

This study will examine whether combining sirolimus (also called rapamycin) with intravenous esketamine may reduce depression symptoms in adults whose depression did not improve sufficiently after a previous course of intravenous esketamine. Researchers will also assess side effects and how long any improvement lasts.

Approximately 40 adults aged 18 to 60 years will participate at two centers in Sao Paulo State, Brazil. All participants will receive the same treatment: eight esketamine infusions over 4 weeks and a dose of oral sirolimus before the first infusion of each week. There is no placebo group.

After providing informed consent, potential participants will undergo interviews, questionnaires, medical assessments, laboratory testing, and review of records from their previous treatment. Eligible participants will complete symptom questionnaires and clinical ratings before and during treatment and at follow-up visits through Week 12. Dissociation and sedation will be assessed before each infusion and at 40 and 120 minutes after the infusion starts. Additional depression ratings will be obtained 24 hours after the first and last infusions. Clinical monitoring and discharge decisions will be managed by the treating hospital team.

The main outcome is the change in clinician-rated depression severity from the assessment before the first study dose to Week 5, which is 7 days after the last esketamine infusion.

Read the detailed description

ESKRAP is a phase 2a, open-label, single-arm study evaluating the preliminary antidepressant effects, durability, safety, and tolerability of repeated intravenous esketamine combined with oral sirolimus in adults with major depressive disorder and documented nonresponse to an adequate previous intravenous esketamine course. Approximately 40 participants will be enrolled at two centers in Sao Paulo State, Brazil. The study has no random allocation or comparator group. Findings will be interpreted as preliminary estimates from an uncontrolled study.

Screening and eligibility

Written informed consent is obtained before research procedures. Initial assessment records the current depressive episode and previous treatments, including the number of pharmacological trials, medications, doses and treatment durations, psychotherapy modality and duration, electroconvulsive therapy, and previous ketamine or esketamine courses. With the authorization already documented in the informed consent form, the research team may request relevant records from the treating clinician.

The screening instruments are the Mini International Neuropsychiatric Interview (MINI), Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), Montgomery-Asberg Depression Rating Scale (MADRS; 7-day recall), and screening Columbia-Suicide Severity Rating Scale (C-SSRS). The screening C-SSRS covers lifetime and past-month suicidal ideation and intensity, and lifetime and past-3-month suicidal behavior. ASSIST is used only at screening; it does not by itself establish a substance use disorder diagnosis or its severity. The substance-related exclusion concerns severe substance use disorder that is current or occurred within the preceding 6 months, excluding nicotine and caffeine.

Laboratory and medical findings and documentation of previous esketamine nonresponse are reviewed before the final eligibility decision. Historical depression scale names, assessment dates, and pretreatment and post-treatment scores are documented; different scales are not directly compared to establish prior response. Previous nonresponse is independently adjudicated by two clinicians, with a third clinician resolving disagreement. Final eligibility review and enrollment follow completion of the required screening assessments, examinations, and documentation. Before the first study medication is administered, eligibility is reconfirmed using the Week 1 baseline MADRS and current clinical information. The baseline MADRS is not a duplicate of the screening assessment.

Treatment

Participants receive esketamine 0.375 mg/kg intravenously over 40 minutes, twice weekly for 4 weeks, for a total of eight infusions. Sirolimus 6 mg orally is given approximately 2 hours before the first infusion of each week, for a total of four doses. The two infusions within a week are separated by 2 to 4 days. Eligible participants receiving maintenance esketamine have that regimen replaced by the study infusion schedule during the treatment period, according to the eligibility requirements.

Depression and weekly assessments

The MADRS is administered at the beginning of all eight infusion visits. At the first infusion visit, one MADRS assessment serves as the baseline and first predose assessment and is performed before sirolimus. At the first infusion of Weeks 2, 3, and 4, the weekly MADRS is also performed before sirolimus. At the second infusion of each week, MADRS is performed at the beginning of the visit before esketamine. MADRS is not repeated immediately before the infusion after it has been completed at the beginning of that visit. Additional MADRS assessments occur 24 hours after completion of only the first and eighth infusions.

MADRS uses 7-day recall at screening, baseline, and post-treatment follow-up visits; it uses 24-hour recall at infusion visits 2 through 8 and at the two post-infusion 24-hour assessments. The primary comparison remains the 7-day-recall MADRS assessment at baseline versus Week 5.

The Quick Inventory of Depressive Symptomatology-Self-Report, 16-item version (QIDS-SR16), is the prospective self-report depression measure. PHQ-9 is not administered prospectively. A historical PHQ-9 may still be used as an admissible source of documented prior esketamine nonresponse. QIDS-SR16, the Generalized Anxiety Disorder-7 scale (GAD-7), Brazilian Snaith-Hamilton Pleasure Scale (SHAPS-BR), seven-item Beck Hopelessness Scale (BHS-7), and Clinical Global Impression-Severity scale (CGI-S) are assessed at baseline, before the first infusion of Weeks 2, 3, and 4, and at Weeks 5, 6, 8, 10, and 12. Only the seven BHS-7 items are administered. Clinical Global Impression-Improvement (CGI-I) begins at infusion 2 and is assessed at subsequent infusion visits and follow-up visits, always relative to the Week 1 baseline.

Sleep is assessed with the brief Pittsburgh Sleep Quality Index (B-PSQI) at baseline, Week 4, and Weeks 5, 6, 8, 10, and 12. Health-related quality of life is assessed with SF-12 version 1 at baseline and Weeks 4, 5, and 12; physical and mental component scores are calculated separately, and SF-6D utility is derived from the SF-12 responses. Baseline and Week 12 characterization also includes BIS-11, ASRS v1.1, MSI-BPD, DUREL, and SWEMWBS. MINI and ASSIST are not repeated at baseline or follow-up.

Dissociation, sedation, and clinical safety

The Clinician-Administered Dissociative States Scale (CADSS) and Modified Observer's Assessment of Alertness/Sedation (MOAA/S) are assessed three times per infusion: immediately before intravenous esketamine, 40 minutes after infusion start, and 120 minutes after infusion start. These times are referenced to the actual start of the infusion. The observed postdose CADSS peak is the highest recorded postdose score, not necessarily the 40-minute score; the predose value is its reference. MOAA/S uses the 0-5 scale, with 5 indicating full alertness and lower scores indicating deeper sedation.

For dissociation, the session-specific resolution threshold is the higher of 4 or the same-session predose CADSS total. Time to first documented resolution runs from the first postdose score above that threshold to the first subsequent score at or below it. For sedation, time to first documented recovery runs from the first postdose MOAA/S score below 5 to the first subsequent score of 5. These are observed assessment times; recovery between assessments is not assigned an exact unobserved time. Sessions with an observed episode but no documented recovery are censored at the last scored assessment. Additional clinical scale assessments contribute only when their actual scores and times are documented and available.

Follow-up C-SSRS, Beck Scale for Suicide Ideation (BSI), and Altman Self-Rating Mania Scale (ASRM) are assessed at baseline, at the beginning of subsequent infusion visits, and at Weeks 5, 6, 8, 10, and 12. Follow-up C-SSRS questions cover the interval since the last C-SSRS actually completed. Adverse events, concomitant medications, vital signs, and other protocol-specified safety assessments are reviewed throughout the relevant study periods. Infection surveillance includes in-person infectious disease assessments during each treatment week and at Weeks 5 and 6, with follow-up surveillance through Week 12.

The treating hospital team remains responsible for clinical observation, treatment of acute adverse effects, and discharge. Participants remain under clinical observation for at least 2 hours after infusion completion, or longer if clinically indicated. The three scheduled research scale assessments do not replace this observation or the clinical discharge criteria.

Follow-up and outcomes

Post-treatment visits occur at Weeks 5, 6, 8, 10, and 12. The primary outcome is change in MADRS total score from the Week 1 predose baseline to Week 5, 7 days after the final infusion. Secondary assessments address response, partial response, remission, depressive symptom severity, persistence of improvement, relapse among Week 5 responders, anxiety, anhedonia, hopelessness, sleep, quality of life, and safety. Historical treatment information and baseline characterization measures support eligibility and descriptive analyses; collecting them does not make each item a separate efficacy outcome.

03

Conditions studied

  • Treatment Resistant Depression (TRD)

Keywords

  • Esketamine
  • Sirolimus
  • Rapamycin
  • Intravenous Esketamine
  • Esketamine Nonresponse
  • Antidepressant Augmentation
  • Combination Therapy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18 to 60 years, inclusive.
  2. Meet criteria for major depressive disorder, with the first major depressive episode occurring before age 50 years.
  3. Previous adequate intravenous esketamine treatment with documented nonresponse, meeting all applicable requirements below:

    • Completed an intravenous esketamine induction course administered twice weekly for 4 to 6 weeks, with a dose of at least 0.5 mg/kg at every session and no upper dose limit for the qualifying prior course.
    • Nonresponse is defined as less than a 50% reduction in total depression severity score from the documented pre-course assessment to the documented end-of-course assessment obtained in routine clinical care. Acceptable instruments are the Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale, Beck Depression Inventory (original or second edition), Patient Health Questionnaire-9 (PHQ-9), Quick Inventory of Depressive Symptomatology (clinician-rated or self-report), or Inventory of Depressive Symptomatology. The same instrument must be used at both assessments; scores from different instruments cannot be compared. The pre-course score is the last documented assessment before the first infusion. The end-of-course score is an assessment performed at the last infusion or within 4 weeks afterward; if several are available, the assessment closest to the last infusion is used.
    • MADRS total score of at least 22 at screening and again at the Week 1 predose visit, with less than a 25% reduction from screening to baseline, calculated as 100 × (screening score - baseline score) / screening score. An increase in MADRS score does not by itself violate this numerical criterion; all other clinical eligibility criteria must still be met. Both assessments are performed prospectively by an independent certified rater.
    • The participant has remained in the same major depressive episode since the prior course, without an intervening period of remission, and has not initiated a new antidepressant, augmentation agent, electroconvulsive therapy, or other neuromodulation treatment between the end of that course and screening.
    • Eligibility may be established through either of two entry pathways:

      1. Nonresponse to induction without subsequent maintenance: the last induction infusion occurred at least 4 weeks and no more than 6 months before the Week 1 visit, and no ketamine or esketamine by any route was received during the 4 weeks before Week 1.
      2. Persistent nonresponse during maintenance: after nonresponse to the qualifying induction course, the participant continued ketamine or esketamine maintenance and remains a nonresponder. The minimum 4-week interval and maximum 6-month interval from induction do not apply. The most recent documented depression assessment during maintenance must show less than a 50% reduction from the pre-induction score using the same instrument. The screening and Week 1 predose MADRS assessments must both be performed while the participant remains on the maintenance regimen.
    • Participants entering through the maintenance pathway must also meet the maintenance requirements: documented nonresponse or intolerance at the maximum dose of the maintenance regimen used (84 mg per administration for intranasal esketamine, or at least 0.5 mg/kg per session for intravenous esketamine); maintenance dose, route, and administration interval unchanged for at least 4 weeks before Week 1; and the last maintenance administration at least 2 days before the first study infusion. No additional maintenance is required. During the 4-week study treatment period, the maintenance regimen is suspended and replaced by the study schedule.
  4. If oral antidepressants are prescribed, their doses have been stable for at least 4 weeks before enrollment. No new antidepressant therapy may be initiated during the study. Monoamine oxidase inhibitors are permitted with the same period of dose stability and intensified vital-sign monitoring, particularly blood pressure.
  5. Clinically stable, as determined by medical history, physical and psychological examinations, 12-lead (ECG), vital signs, and laboratory assessments, including complete blood count, liver enzymes, lipid panel, serum chemistry, and urinalysis. Baseline laboratory results and ECG from medical records may be accepted if obtained no more than 70 days before study treatment begins. A participant with a clinical abnormality may be included only if the investigator considers that the abnormality will not introduce additional risk or interfere with study objectives; specific exclusion criteria must still be satisfied.
  6. Women of must agree to use a highly effective method from until at least 3 months after the last dose of study medication. Acceptable methods are an intrauterine device, intrauterine system, contraceptive implant, combined injectable contraceptive, or hormonal oral contraceptive used together with a male condom with spermicide. Sexual abstinence is acceptable when consistent with the participant's usual and preferred lifestyle.
  7. Men who are sexually active with partners of childbearing potential must agree to use condoms from informed consent until 3 months after the last dose. Their partners must be willing to use a highly effective contraceptive method from screening until 1 month after the last dose. Men must agree not to donate semen during the study and for 3 months after the last dose.
  8. Agree to avoid prescription and nonprescription medications, herbal remedies, and dietary supplements during the study unless prescribed or approved by the study investigators.
  9. Able to provide written informed consent, personally signed and dated, before any study-related procedure.
  10. Fluent in Portuguese, with sufficient understanding to communicate adequately with the principal investigators and study coordinator and to complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  1. Any active or serious medical condition that could compromise participant safety, expose the participant to undue risk, or interfere with study objectives.
  2. Reactive screening serology for (HIV), surface antigen (HBsAg), or antibody (anti-HCV), regardless of previous treatment or an undetectable viral load.
  3. Reactive interferon-gamma release assay (IGRA) at screening, or clinical or radiographic evidence of active tuberculosis. A reactive IGRA is exclusionary even with a history of adequately documented prior tuberculosis treatment.
  4. Reactive syphilis serology at screening on either a treponemal or nontreponemal test, regardless of documented previous treatment.
  5. History of solid-organ or bone marrow transplantation.
  6. History of a seizure disorder, except febrile seizures in childhood.
  7. within the past 5 years, except adequately treated basal cell carcinoma of the skin or cervical carcinoma in situ/dysplasia.
  8. Use of prohibited concomitant medications or products, or use incompatible with the protocol restrictions. Strong /P-glycoprotein inhibitors (for example, ketoconazole, itraconazole, clarithromycin, ritonavir, or voriconazole), strong CYP3A4/P-glycoprotein inducers (for example, rifampin, rifabutin, carbamazepine, phenytoin, or St. John's wort), and other products are prohibited. Initiating a new antidepressant or changing antidepressant doses during the study is prohibited. Grapefruit, grapefruit juice, and Seville oranges must be avoided. Live or are prohibited during the interval specified in exclusion criterion 17. Monoamine oxidase inhibitors are permitted with doses stable for at least 4 weeks and intensified monitoring, as specified in inclusion criterion 4.
  9. Vital signs at the time of treatment outside any of the following limits without assessment and clearance by a healthcare professional: systolic blood pressure below 85 or above 145 mmHg; diastolic blood pressure below 55 or above 95 mmHg; or resting heart rate below 45 or above 100 beats per minute.
  10. Current diagnosis of schizophrenia, schizoaffective disorder, bipolar I or II disorder, or a neurodegenerative disorder; or a personality disorder that, in the investigator's judgment, could interfere with study participation.
  11. Current severe suicide risk, assessed by the responsible investigator, defined as a score of 4 or 5 on the Suicidal Ideation subscale of the Columbia-Suicide Severity Rating Scale (C-SSRS), or a score of at least 5 on MADRS item 10.
  12. Current severe substance use disorder, or severe substance use disorder within the 6 months before enrollment, according to DSM-5-TR criteria, excluding nicotine and caffeine use disorders.
  13. Positive pregnancy test or current breastfeeding.
  14. Known or intolerance to esketamine, ketamine, sirolimus, or any .
  15. Heparin sensitivity or heparin-induced thrombocytopenia.
  16. Current systemic infection or febrile illness.
  17. Receipt or planned receipt of a live or live-attenuated vaccine within 4 weeks before, during, or within 4 weeks after the study treatment period.
  18. Participation in another clinical study involving an active therapeutic intervention or an investigational device within 3 months before the first dose of study medication.
  19. A laboratory abnormality, including (AST) or alanine aminotransferase (ALT) above 2 times the (ULN), or total above 1.5 times ULN, within 2 weeks of the first administration of study medication.
  20. Fasting triglycerides above 500 mg/dL or fasting total cholesterol above 350 mg/dL.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intravenous Esketamine Plus Oral Sirolimus

    Participants receive intravenous esketamine 0.375 mg/kg infused over 40 minutes twice weekly for 4 weeks, for a total of eight infusions. Oral sirolimus 6 mg, administered as three 2 mg tablets, is given under direct observation approximately 2 hours before the first esketamine infusion of each week, for a total of four doses. No additional sirolimus dose is given before the second infusion of the week. Participants are followed for 8 weeks after the treatment period.

    Drug: Esketamine · Drug: Sirolimus (RAPAMUNE)

Interventions

  • DrugEsketamine

    Esketamine hydrochloride is administered intravenously at 0.375 mg/kg over 40 minutes, twice weekly for 4 consecutive weeks, for a total of eight infusions. Infusions are separated by 2 to 4 days and are administered at the study center under medical supervision, with clinical monitoring during infusion and observation for at least 2 hours after each infusion ends.

    Also known as: S-ketamine, Esketamine hydrochloride

  • DrugSirolimus (RAPAMUNE)

    Sirolimus is administered orally at 6 mg, as three 2 mg Rapamune tablets, once weekly for 4 consecutive weeks, for a total of four doses. Each dose is administered under direct observation at the study center approximately 2 hours before the first esketamine infusion of that week. No additional sirolimus dose is administered before the second weekly esketamine infusion.

    Also known as: Rapamycin

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 5

    Mean change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline to Week 5, assessed by independent certified raters. The MADRS is a clinician-rated scale comprising 10 items scored from 0 to 6, with a total score ranging from 0 to 60. Higher scores indicate greater depressive symptom severity. Change is calculated as the Week 5 score minus the baseline score; negative values indicate improvement.

    Time frame: Baseline (Week 1, before the first study dose) and Week 5 (7 days after the last esketamine infusion)

Secondary outcomes

  1. Percentage of Participants With Depression Response

    Percentage of participants with a reduction of at least 50% in Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline, calculated separately at each specified visit. The MADRS contains 10 items and has a total score ranging from 0 to 60; higher scores indicate more severe depressive symptoms. Baseline is the Week 1 predose assessment.

    Time frame: Baseline (Week 1, predose) and Weeks 5, 6, 8, 10, and 12

  2. Percentage of Participants With at Least Partial Depression Response

    Percentage of participants with a reduction of at least 25% in Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline, calculated separately at each specified visit. This protocol-defined threshold includes participants with reductions of 50% or greater. MADRS total scores range from 0 to 60; higher scores indicate more severe depressive symptoms. Baseline is the Week 1 predose assessment.

    Time frame: Baseline (Week 1, predose) and Weeks 5, 6, 8, 10, and 12

  3. Percentage of Participants With Depression Remission

    Percentage of participants with a Montgomery-Asberg Depression Rating Scale (MADRS) total score of 10 or lower, calculated separately at each specified visit. MADRS total scores range from 0 to 60; higher scores indicate more severe depressive symptoms.

    Time frame: Weeks 5, 6, 8, 10, and 12

  4. Percentage of Participants With a MADRS Total Score Below 19

    Percentage of participants with a Montgomery-Asberg Depression Rating Scale (MADRS) total score below 19, calculated separately at each specified visit. This threshold includes participants meeting the remission criterion. MADRS total scores range from 0 to 60; higher scores indicate more severe depressive symptoms.

    Time frame: Weeks 5, 6, 8, 10, and 12

  5. Change From Baseline in Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16) Total Score

    Mean change from baseline in QIDS-SR16 total score at the specified post-baseline visits, analyzed using a mixed model for repeated measures. The questionnaire contains 16 items covering nine depressive symptom domains. Domain scores are combined to produce a total score ranging from 0 to 27. Higher scores indicate more severe depressive symptoms. Change is calculated as the post-baseline score minus the baseline score; negative values indicate improvement.

    Time frame: Baseline (Week 1, predose) and Weeks 2, 3, 4, 5, 6, 8, 10, and 12

  6. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score

    Mean change from baseline in CGI-S score at the specified post-baseline visits, analyzed using a mixed model for repeated measures. The CGI-S is a clinician-rated measure of overall illness severity, ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Change is calculated as the post-baseline score minus the baseline score; negative values indicate improvement.

    Time frame: Baseline (Week 1, predose) and Weeks 2, 3, 4, 5, 6, 8, 10, and 12

  7. Clinical Global Impression-Improvement (CGI-I) Score

    Mean CGI-I score, calculated separately at each specified post-baseline visit. The CGI-I is a clinician-rated assessment of overall improvement or worsening relative to baseline. Scores range from 1 (very much improved) to 7 (very much worse), with 4 indicating no change. Each rating refers to the participant's condition at baseline; no baseline CGI-I score is subtracted.

    Time frame: Before infusions 2-8 during Weeks 1-4 and at Weeks 5, 6, 8, 10, and 12, relative to the Week 1 baseline before the first study dose.

  8. Change in MADRS Total Score From Week 5 During Follow-Up

    Mean change in Montgomery-Asberg Depression Rating Scale (MADRS) total score from Week 5 to each specified follow-up visit. Change is calculated as the follow-up score minus the Week 5 score. MADRS total scores range from 0 to 60; higher scores indicate more severe depressive symptoms. Positive changes indicate worsening relative to Week 5, and negative changes indicate further improvement.

    Time frame: Week 5 and follow-up assessments at Weeks 6, 8, 10, and 12

  9. Time to Depression Relapse Among Week 5 Responders

    Time from the Week 5 assessment to the first follow-up assessment showing loss of at least 50% of the improvement in MADRS total score achieved from baseline to Week 5, or a MADRS total score of at least 22, whichever occurs first. Week 5 responders are participants with a reduction of at least 50% from baseline. Time to relapse will be analyzed using Kaplan-Meier methods; participants without observed relapse will be censored at their last assessment.

    Time frame: Week 5 through Week 12; relapse assessed at Weeks 6, 8, 10, and 12

  10. Change From Baseline in Generalized Anxiety Disorder-7 (GAD-7) Total Score

    Mean change from baseline in GAD-7 total score at the specified post-baseline visits, analyzed using a mixed model for repeated measures. The GAD-7 contains seven self-report items scored from 0 to 3, yielding a total score ranging from 0 to 21. Higher scores indicate greater anxiety severity. Change is calculated as the post-baseline score minus the baseline score; negative values indicate improvement.

    Time frame: Baseline (Week 1, predose) and Weeks 2, 3, 4, 5, 6, 8, 10, and 12

  11. Change From Baseline in Brazilian Snaith-Hamilton Pleasure Scale (SHAPS-BR) Total Score

    Mean change from baseline in SHAPS-BR total score at the specified post-baseline visits, analyzed using a mixed model for repeated measures. The SHAPS-BR assesses anhedonia using 14 items scored 0 or 1 according to the Brazilian version. Total scores range from 0 to 14; higher scores indicate greater anhedonia. Change is calculated as the post-baseline score minus the baseline score; negative values indicate improvement.

    Time frame: Baseline (Week 1, before the first study dose) and Weeks 2, 3, 4, 5, 6, 8, 10, and 12.

  12. Change From Baseline in Seven-Item Beck Hopelessness Scale (BHS-7) Total Score

    Mean change from baseline in BHS-7 total score at the specified post-baseline visits, analyzed using a mixed model for repeated measures. The seven-item scale assesses hopelessness using items scored 0 or 1, yielding a total score ranging from 0 to 7. Higher scores indicate greater hopelessness. Change is calculated as the post-baseline score minus the baseline score; negative values indicate improvement.

    Time frame: Baseline (Week 1, before the first study dose) and Weeks 2, 3, 4, 5, 6, 8, 10, and 12.

  13. Change From Baseline in Brief Pittsburgh Sleep Quality Index (B-PSQI) Total Score

    Mean change from baseline in B-PSQI total score at the specified post-baseline visits, analyzed using a mixed model for repeated measures. The B-PSQI uses six questions to derive five sleep-quality components, producing a total score ranging from 0 to 15. Higher scores indicate poorer sleep quality. Change is calculated as the post-baseline score minus the baseline score; negative values indicate improvement.

    Time frame: Baseline (Week 1, predose) and Weeks 4, 5, 6, 8, 10, and 12

  14. Percentage of Week 5 Responders Meeting Depression Response Criteria at Follow-Up

    Among participants with a reduction of at least 50% in Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline at Week 5, the percentage who also meet this response criterion at each specified follow-up visit. Percentages are calculated separately for each visit using Week 5 responders as the reference population. MADRS total scores range from 0 to 60; higher scores indicate more severe depressive symptoms.

    Time frame: Week 5 response status and follow-up assessments at Weeks 6, 8, 10, and 12; baseline reference at Week 1

  15. Change From Baseline in SF-12 Physical Component Summary Score

    Mean change from baseline in the Physical Component Summary (PCS) score of the 12-Item Short Form Health Survey, version 1 (SF-12v1), at each specified post-baseline visit. The questionnaire assesses health-related quality of life over the preceding 4 weeks. Scores are calculated using the original US norm-based algorithm, with a reference population mean of 50 and standard deviation of 10. Possible scores range from approximately 9.95 to 70.13; higher scores indicate better physical health-related quality of life. Change is the post-baseline score minus the baseline score; positive values indicate improvement. Repeated assessments will be analyzed using a mixed model for repeated measures.

    Time frame: Baseline (Week 1, predose) and Weeks 4, 5, and 12

  16. Change From Baseline in SF-12 Mental Component Summary Score

    Mean change from baseline in the Mental Component Summary (MCS) score of the 12-Item Short Form Health Survey, version 1 (SF-12v1), at each specified post-baseline visit. The questionnaire assesses health-related quality of life over the preceding 4 weeks. Scores are calculated using the original US norm-based algorithm, with a reference population mean of 50 and standard deviation of 10. Possible scores range from approximately 5.89 to 72.28; higher scores indicate better mental health-related quality of life. Change is the post-baseline score minus the baseline score; positive values indicate improvement. Repeated assessments will be analyzed using a mixed model for repeated measures.

    Time frame: Baseline (Week 1, predose) and Weeks 4, 5, and 12

  17. Change From Baseline in SF-6D Health Utility Index

    Mean change from baseline in the Short Form Six-Dimension (SF-6D) health utility index at each specified post-baseline visit. Scores are derived from individual SF-12v1 item responses using the SF-12-specific algorithm and UK general population preference weights published by Brazier and Roberts (2004). The measure covers physical functioning, role limitations, social functioning, pain, mental health, and vitality. Scores range from 0.345 to 1.000; higher values indicate better health-related quality of life, and 1.000 represents full health. Change is the post-baseline value minus the baseline value; positive values indicate improvement.

    Time frame: Baseline (Week 1, predose) and Weeks 4, 5, and 12

  18. Suicidal Ideation and Suicidal Behavior

    Suicidality is assessed with the Columbia-Suicide Severity Rating Scale (C-SSRS) and Beck Scale for Suicide Ideation (BSI). C-SSRS results are participant counts by ideation and behavior category. Baseline and later assessments cover the interval since the last completed C-SSRS; lifetime screening findings are distinguished from interval findings. BSI items 1-5 yield a screening subtotal of 0-10. The 19-item total (0-38) is calculated only when all 19 items are applicable and completed. When items 4 and 5 are both zero, items 6-19 are skipped, the full total remains unavailable, and the subtotal is retained; skipped items are not assigned zero. Higher BSI scores indicate greater suicidal ideation severity. Scoring paths and available denominators are reported. C-SSRS categories, BSI subtotal and BSI full total are summarized separately by visit; no combined score is calculated.

    Time frame: Before the first study dose at Week 1 baseline, at the start of infusion visits 2-8 during Weeks 1-4, and at Weeks 5, 6, 8, 10, and 12. C-SSRS intervals begin at the last completed C-SSRS assessment.

  19. Altman Self-Rating Mania Scale (ASRM) Total Score

    Mean total score on the Altman Self-Rating Mania Scale (ASRM), calculated separately at each specified visit. The ASRM is a self-report measure of manic symptoms comprising five items scored from 0 to 4. Total scores range from 0 to 20; higher scores indicate greater severity of manic symptoms. Baseline and post-baseline scores are summarized by visit.

    Time frame: Before the first study dose at Week 1 baseline, at the start of infusion visits 2-8 during Weeks 1-4, and at Weeks 5, 6, 8, 10, and 12.

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    Number of participants with at least one adverse event that begins or worsens after the first study dose. Events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by system organ class, preferred term, severity, seriousness, and relationship to each study drug. Participants with any adverse event and those with serious adverse events will be reported separately. Each participant will be counted once within each reported category.

    Time frame: From the first study dose through Week 12

  2. Dissociative Symptoms Assessed With the Clinician-Administered Dissociative States Scale (CADSS)

    CADSS total scores, changes from same-session predose scores, highest observed postdose score, percentage with a postdose score above 4, and time to first documented resolution will be reported separately by infusion visit; no composite score is calculated. CADSS has 23 items scored 0-4, totaling 0-92; higher scores indicate greater dissociation. Postdose minus predose changes above zero indicate worsening. The peak excludes predose. Resolution time is minutes from the first postdose score above max(4, predose score) to the first subsequent score at or below that threshold, using actual assessment times. With no observed episode, time is not applicable; unresolved episodes are censored at the last scored assessment. Additional clinical assessments contribute only if actual scores and times are documented. Discharge alone does not establish resolution; recovery between observed assessments is not imputed.

    Time frame: Immediately before infusion and 40 and 120 minutes after infusion start, at each of eight infusion visits during Weeks 1-4; additional scored clinical assessments during the visit, if documented.

  3. Sedation Assessed With the Modified Observer's Assessment of Alertness/Sedation (MOAA/S)

    MOAA/S scores, lowest observed postdose score, percentage with a postdose score of 3 or lower, time to first documented recovery, and percentage requiring clinical intervention for sedation will be reported separately by infusion visit; no composite is calculated. MOAA/S ranges from 0 (no response to painful stimulation) to 5 (fully alert); lower scores indicate deeper sedation. The postdose minimum excludes predose. Recovery time is minutes from the first postdose score below 5 to the first subsequent score of 5, using actual assessment times. With no observed sedation, time is not applicable; unresolved episodes are censored at the last scored assessment. Additional scores contribute only if documented with actual times; discharge alone is not scored recovery. Predose sedation is described separately. Clinical interventions are documented measures specifically required to manage sedation beyond routine observation.

    Time frame: Predose and 40 and 120 minutes after infusion start at each of eight visits in Weeks 1-4; additional scored clinical assessments if documented, and sedation-related interventions through the end of clinical observation.

  4. Number of Participants With Clinically Significant Treatment-Emergent Clinical or Laboratory Abnormalities

    Number of participants with at least one new or worsened abnormality after the first study dose judged clinically significant by the investigator, considering protocol safety criteria, local reference ranges and clinical context; the rationale is documented. Out-of-range values alone do not establish clinical significance. Each participant is counted once overall and once in each applicable category: cardiovascular (blood pressure, heart rate, ECG); hematologic (hemoglobin, hematocrit, leukocytes, absolute neutrophils, platelets); hepatic (ALT, AST, total bilirubin); fasting lipids (total, LDL and HDL cholesterol, triglycerides); or physical examination. Categories may overlap and are not summed. Pretreatment laboratory results, including the Week 1 predose blood count, and predose clinical findings provide baseline references. Baseline abnormalities count only if they worsen after dosing. Serology results used solely for screening eligibility are excluded.

    Time frame: First dose through Week 12: vitals at infusions and Weeks 5,6,8,10,12; ECG Weeks 4,5,12; examination Weeks 4,12; CBC before weekly sirolimus in Weeks 1-4; ALT, AST, bilirubin and fasting lipids Week 5; other labs as clinically indicated.

  5. Number of Participants With Treatment-Emergent Infections

    Number of participants with at least one new or worsened infection after the first study dose, identified through directed clinical surveillance and investigator assessment. Surveillance includes in-person assessments by an infectious disease physician during Weeks 1-4 and at Weeks 5 and 6, with continued infection surveillance at Weeks 8, 10, and 12. Infections will be recorded regardless of their assessed relationship to either study drug and summarized by infection type, severity, seriousness, and causality. Each participant will be counted once in the overall infection count.

    Time frame: From the first study dose through Week 12

07

Study locations

2 sites
  • Centro Integrado de Saúde Mental (CISM)
    Indaiatuba, São Paulo, Brazil
  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, São Paulo, Brazil
08

References and documents

Publications

  • Su T, Chen MH. Modulation of the antidepressant response of ketamine by an immunosuppressant rapamycin: a prospective randomized, double-blind, placebo controlled study in the patients with refractory depression [conference abstract]. Int J Neuropsychopharmacol. 2025;28(Suppl 1):i315. doi:10.1093/ijnp/pyae059.561.
  • Stanfield B, Leroux B, Kaeberlein M, Jones J, Lucas R. Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 Randomised, Double-Blind, Placebo-Controlled Trial. J Cachexia Sarcopenia Muscle. 2026 Apr;17(2):e70274. doi: 10.1002/jcsm.70274. PubMed 41985884 ↗
  • Lee DJW, Hodzic Kuerec A, Maier AB. Targeting ageing with rapamycin and its derivatives in humans: a systematic review. Lancet Healthy Longev. 2024 Feb;5(2):e152-e162. doi: 10.1016/S2666-7568(23)00258-1. PubMed 38310895 ↗
  • Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, Caliman-Fontes AT, Echegaray MVF, Bandeira ID, Silva SS, Cavalcanti DE, Araujo-de-Freitas L, Sarin LM, Tuena MA, Nakahira C, Sampaio AS, Del-Porto JA, Turecki G, Loo C, Lacerda ALT, Quarantini LC. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. J Affect Disord. 2020 Mar 1;264:527-534. doi: 10.1016/j.jad.2019.11.086. Epub 2019 Nov 14. PubMed 31786030 ↗
  • Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC, Van Nueten L. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. Biol Psychiatry. 2016 Sep 15;80(6):424-431. doi: 10.1016/j.biopsych.2015.10.018. Epub 2015 Nov 3. PubMed 26707087 ↗
  • Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, Sherif M, Ahn KH, D'Souza DC, Formica R, Southwick SM, Duman RS, Sanacora G, Krystal JH. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology. 2020 May;45(6):990-997. doi: 10.1038/s41386-020-0644-9. Epub 2020 Feb 24. PubMed 32092760 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying published study results, together with a data dictionary, the study protocol, and the statistical analysis plan, will be made available to qualified researchers upon reasonable request to the principal investigators. Access will be subject to a data use agreement, applicable Brazilian data protection requirements (LGPD), participant consent provisions, sponsor-investigator data rights, and the applicable clinical study and confidentiality agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Individual participant data and supporting documents will be available immediately after publication of the main study results and for 5 years thereafter.

Access criteria: Qualified researchers may request de-identified individual participant data underlying published study results, the data dictionary, study protocol, and statistical analysis plan directly from the principal investigators. Requests may concern secondary analyses related to the study objectives and consistent with participant consent. Access will be subject to a data use agreement, applicable Brazilian data protection requirements (LGPD), sponsor-investigator data rights, and the applicable clinical study and confidentiality agreements.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949500
Lead sponsor
Rodolfo Furlan Damiano
Collaborators
Freedom Biosciences, Yale University
Responsible party
Rodolfo Furlan Damiano (Postdoctoral Researcher, University of Sao Paulo) — Sponsor-investigator
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Rodolfo F Damiano, MD, PhD
Contact
damianorf@usp.br
+55 11 92661-9090

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion